Ubs Group Ag Entera Bio Ltd. Transaction History

Ubs Group Ag

$611 Billion
Q3 2025

A detailed history of Ubs Group Ag transactions in Entera Bio Ltd. stock. As of the latest transaction made, Ubs Group Ag holds 10,452 shares of ENTX stock, worth $28,324. This represents 0.0% of its overall portfolio holdings.

Number of Shares

10,452

Previous 15,631 33.13%

Holding current value

$28,324

Previous $29,000 34.48%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	SELL	$1.73 - $2.16 $8,959 - $11,186	-5,179 Reduced 33.13%	10,452 $19,000
Q2 2025 Aug 14, 2025	BUY	$1.6 - $2.36 $25,009 - $36,889	15,631 New	15,631 $29,000
Q3 2024 Nov 14, 2024	SELL	$1.48 - $2.14 $36,816 - $53,234	-24,876 Reduced 14.84%	142,747 $271,000
Q2 2024 Aug 13, 2024	BUY	$1.73 - $2.98 $30,714 - $52,906	17,754 Added 11.85%	167,623 $308,000
Q1 2024 May 13, 2024	BUY	$0.64 - $1.72 $95,916 - $257,774	149,869 New	149,869 $250,000

Q3 2023 Nov 09, 2023	SELL	$0.6 - $0.88 $270 - $396	-450 Reduced 42.29%	614 $0
Q2 2023 Aug 11, 2023	SELL	$0.68 - $1.01 $5,899 - $8,762	-8,676 Reduced 89.08%	1,064 $0
Q1 2023 May 12, 2023	SELL	$0.83 - $1.44 $537 - $933	-648 Reduced 6.24%	9,740 $11,000
Q4 2022 Feb 08, 2023	BUY	$0.5 - $1.05 $4,317 - $9,065	8,634 Added 492.25%	10,388 $7,000
Q3 2022 Nov 10, 2022	SELL	$0.07 - $1.98 $395 - $11,187	-5,650 Reduced 76.31%	1,754 $2,000
Q2 2022 Aug 10, 2022	BUY	$1.33 - $2.95 $3,649 - $8,094	2,744 Added 58.88%	7,404 $10,000
Q1 2022 May 16, 2022	BUY	$1.91 - $3.23 $8,900 - $15,051	4,660 New	4,660 $13,000
Q4 2021 Feb 14, 2022	SELL	$2.82 - $4.79 $1,593 - $2,706	-565 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$4.43 - $6.29 $2,024 - $2,874	-457 Reduced 44.72%	565 $3,000
Q2 2021 Aug 13, 2021	SELL	$2.92 - $6.5 $1,728 - $3,848	-592 Reduced 36.68%	1,022 $6,000
Q1 2021 May 12, 2021	BUY	$1.16 - $6.9 $1,327 - $7,893	1,144 Added 243.4%	1,614 $6,000
Q4 2020 Feb 11, 2021	SELL	$1.03 - $1.24 $7,589 - $9,136	-7,368 Reduced 94.0%	470 $1,000
Q3 2020 Nov 12, 2020	SELL	$1.05 - $2.2 $2,671 - $5,596	-2,544 Reduced 24.5%	7,838 $10,000
Q2 2020 Jul 31, 2020	BUY	$1.71 - $3.01 $17,753 - $31,249	10,382 New	10,382 $19,000
Q1 2020 May 01, 2020	SELL	$1.6 - $3.34 $992 - $2,070	-620 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$1.84 - $2.97 $285 - $460	155 Added 33.33%	620 $1,000
Q3 2019 Nov 14, 2019	SELL	$2.11 - $3.75 $468 - $832	-222 Reduced 32.31%	465 $1,000
Q2 2019 Aug 14, 2019	SELL	$2.92 - $4.4 $1,314 - $1,980	-450 Reduced 39.58%	687 $2,000
Q1 2019 May 14, 2019	BUY	$3.01 - $4.84 $3,422 - $5,503	1,137 New	1,137 $5,000
Q4 2018 Feb 14, 2019	SELL	$3.0 - $5.85 $1,095 - $2,135	-365 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$4.5 - $6.7 $4,833 - $7,195	-1,074 Reduced 74.64%	365 $2,000
Q2 2018 Aug 14, 2018	BUY	$6.28 - $6.3 $9,036 - $9,065	1,439 New	1,439 $9,000

Others Institutions Holding ENTX

# of Institutions

Shares Held

9.21M

Call Options Held

21.1K

Put Options Held

View Full List

About Entera Bio Ltd.

Ticker ENTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,809,900
Market Cap $78.1M
Description
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed ...

More about ENTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account